Skip to content

Research on Helicobacter pylori Resistance to Amoxicillin

Research on Helicobacter pylori Resistance to Amoxicillin

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116359
Enrollment
Unknown
Registered
2026-01-08
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Amoxicillin-resistant group:None
The group that is not resistant to amoxicillin:None

Sponsors

Huzhou Center Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged between 16 and 80 years; 2. Patients who have lived in the local area for a long time (residence time >=5 years); 3. Patients with stable conditions and no severe systemic diseases; 4. Complete clinical data; 5. Patients who have given informed consent and signed the relevant consent forms for endoscopy, HP culture, and drug susceptibility testing; 6. At least one positive result on the 13C-urea breath test.

Exclusion criteria

Exclusion criteria: 1. Patients with contraindications to gastroscopy or those who have difficulty cooperating with the procedure; 2. Patients who have previously undergone gastrointestinal surgery or have gastrointestinal malignancies; 3. Patients with gastrointestinal bleeding, gastrointestinal ulcer perforation, or pyloric obstruction; 4. Patients who have taken antibiotics, bismuth agents, traditional Chinese medicine, proton pump inhibitors, H2 receptor antagonists, P-CABs, or other drugs that may affect test results within the past month; 5. Patients with severe underlying conditions such as heart, lung, liver, or kidney dysfunction, or severe psychiatric disorders; 6. Pregnant or breastfeeding women; 7. Drug allergies: patients allergic to study medications including penicillin, PPIs, furazolidone, or potassium bismuth citrate.

Design outcomes

Primary

MeasureTime frame
eradication rate;Minimal Inhibit Concentration;

Secondary

MeasureTime frame
Ampicillin resistance gene detection;The change in amoxicillin resistance rate;

Countries

China

Contacts

Public ContactJiang Liu

Huzhou Center Hospital

liujiangxm2013@163.com+86 572 2023301

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026